Short answer
Some cancer blood tests look for methylation patterns in cell-free DNA, and some also combine those signals with DNA fragmentation or protein markers. That is a real area of cancer-detection research, but a detectable signal is not the same thing as proven screening benefit. For consumers, the key question is whether the exact test has evidence for the claimed use, not just whether it can find a molecular pattern.
What the tests measure
| Signal | What it may help with | What it does not prove |
|---|---|---|
| DNA methylation patterns | Can suggest that tumor DNA is present in blood. | Does not by itself diagnose cancer or prove screening benefit. |
| Organ-site prediction | May estimate where a signal is coming from. | Follow-up imaging or biopsy is still needed to confirm cancer and location. |
| Multi-signal panels | May combine methylation with other analytes. | A broader panel is still not the same as validated population screening. |
Claims to separate
| Claim | Question to ask | Why it matters |
|---|---|---|
| Finds a cancer signal | What cancers, stages, and populations were studied? | Performance can vary widely by cancer type, stage, and whether people had symptoms. |
| Predicts tissue of origin | How often is the predicted source correct? | Wrong-location guesses can lead to extra imaging and procedures. |
| Improves outcomes | Has the test shown fewer late-stage cancers or lower mortality? | Detection alone is not the same as proven screening benefit. |
| Replaces standard screening | Which guideline-backed tests still apply? | Established screening remains the backbone of cancer prevention and early detection. |
What a cautious consumer should check
Ask whether the test is FDA-cleared or approved for the claimed use, whether it is ordered by a clinician or sold directly, and whether it is meant for screening, diagnosis, or recurrence monitoring. In general, emerging cancer blood tests should not replace mammograms, cervical screening, colorectal screening, lung cancer screening when eligible, or other guideline-backed tests.
Questions to ask
- Is this a methylation-based MCED test, a single-cancer test, or a recurrence-monitoring test?
- Was the test validated for screening people like me, or for people already diagnosed with cancer?
- What happens after a positive result if imaging does not find cancer?
- Which guideline-backed screenings should I still complete?
- How many false positives and false negatives were seen in the study group?
Related guides: multi-cancer early detection blood test claims, consumer Alzheimer's blood biomarker test claims, consumer organ-age testing claims, and consumer proteomics testing claims.
FAQ
What is an MCED or MCD test?
NCI uses MCD for multi-cancer detection, while many companies say MCED for multi-cancer early detection. These blood-based assays try to detect biological signals that can suggest cancer, but they are still prediction tools rather than a diagnosis.
Does a positive result mean I have cancer?
No. A positive result means the test detected a signal that needs follow-up. Imaging, tissue sampling, or other evaluation may still find no cancer.
Can it replace guideline-backed cancer screening?
No. NCI guidance says established screening tests still matter, including mammography, colorectal screening, cervical screening, and lung screening when someone is eligible.
Why can a positive test still end up with no cancer found?
The signal may not be specific enough to localize cancer confidently, or the cancer may be too small or in a location that is hard to find. NCI notes that in published research, more than half of positive MCD tests did not lead to a cancer being found.
Are consumer methylation tests FDA-cleared for screening?
Not automatically. FDA review depends on the exact test, the intended use, and the risk category. Consumers should check whether the specific product is FDA-cleared or approved for the claimed use, or whether it is being offered as an LDT or research-oriented test.
What should I ask before paying for one?
Ask what cancers it was validated for, whether it is intended for screening or another use, what happens after a positive result, and which standard screenings still apply. If the answer is vague, the claim is probably ahead of the evidence.